New Frontiers in Cancer Research: How Chemicals Can Interfere with Cancer Therapies and Implications for Health Policy

October 27, 2011
1:00 pm US Eastern Time

Slides & Resources

Dr. Goodson's presentation slides

Paper: Activation of the mTOR pathway by low levels of xenoestrogens in breast epithelial cells from high-risk women Goodson, et al, Carcinogenesis, 2011

Paper: Bisphenol A Induces a Profile of Tumor Aggressiveness in High-Risk Cells from Breast Cancer Patients, Dairkee, et al, American Association for Cancer Research, 2008

Abstract: Adverse Health Outcomes in Women Exposed In Utero to Diethylstilbestrol
NEJM, October 2011, Referenced by Ted Schettler during his science introduction on the call

Article: Testing Chemicals for Effects on Breast Development, Lactation, and Cancer (PDF), Environmental Health Perspectives, August 2011

Report: Urgent Unanswered Questions About Breast Cancer (PDF), California Breast Cancer Research Program, 2010

Article: Breast Cancer Fund Study: Science or Class Warfare? Trevor Butterworth, Forbes, September 21, 2011

San Francisco Medical Society blog: What's Not on the Can's Label (Editorial on Bisphenol A featuring SFMS member)

Listen to Recording

Widely-noted research published recently indicated that the presence of chemicals like BPA and methylparaben can interfere with commonly used breast cancer therapies. This call was co-sponsored by CHE's Breast Cancer Working Group.

Featured Speakers

William Goodson, MD, the lead author of that study

Mhel Kavanaugh-Lynch, MD, MPH, who discussed health policy opportunities based on this research and other studies associating chemical exposures with breast cancer.

Ted Schettler, MD, MPH, also provided a brief update on new science relevant to this topic.

The call was facilitated by Steve Heilig, San Francisco Medical Society.